Abstract
Metabolite identification and urinary and biliary excretion of the new fluoroquinolone antibacterial agent DW116 [1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1-piperazinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid, hydrochloride] after oral administration have been studied in Sprague-Dawley rats. The excretion kinetics were monoexponential. Most of the drug was eliminated via the hepatic and renal routes. Mean renal clearance of DW116 was 73.4 ml/hr/kg and mean biliary clearance was 83.8 ml/hr/kg. The major metabolite excreted in the bile was identified as the glucuronide ester of the parent drug using base-hydrolysis of the conjugate metabolite followed by co-HPLC with standard compound,19F-NMR and LC-MS methods. The glucuronide conjugate was also found in urine. The mean urinary recoveries of free and total (free plus glucuronide ester) DW116 were 28.6±2.7% and 36.4±1.8% of the administered dose and the corresponding biliary recoveries were 14.4±5.5% and 37.0±7.6%, respectively.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References Cited
Blum, R. A., Influence of renal function on the pharmacokinetics of lomefloxacin compared with other fluoroquinolones.Am. J. Med. 92, S18-S21 (1992).
Chung, B.C. and Jung, B.H., The study on the development of DW116, new quinolone class of antibacterial agent.Korea Institute of Science and Technology Technical Report, 109 (1995)
Lombardi, F., Ardemagni, R., Colzani, V., and Visconti, M., High performance liquid chromatographic determination of rufloxacin and its main active metabilite in biological fluids.J. Chromatogr. B, 576, 129–134 (1992).
Marchbanks, C. R., Dudley, M. N., Flor, S. and Beals, B., Pharmacokinetics and safety of single rising doses of ofloxacin in healthy volunteers.Pharmacotherapy 12, 45–49 (1992).
Montay, G., Bruno, R., Vergniol, J. C., Ebmeier, M., Le Roux Y., Guimart, C., Frydman, A., Chassard, D and Thebault, J. J., Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600 and 800 mg.J. Clin. Pharmacol. 34, 1071–1076 (1994).
Nakagawa, T., Ishigai, M., Miramatusu, Y., Kinoshita, H., Ishitani, Y., Ohkubo, K and Okazaki, A., Determination of the new fluoroquinolone balofloxacin and its metabolites in biological fluids by high performance liquid chromatography.Arznermittelforschung 45, 716–718 (1995).
Stuck, A. E., Kim, D. K. and Freg, F. K., Fleroxacin clinical pharmacokinetics.Clin. Pharmacokinet. 22, 116–131 (1992).
Tai, M., Dmachi, K. and Simizu, Y., Study of metabolism of T-3761 in animals.Jpn. J. Antibiot. 48, 656–664 (1995)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jung, B.H., Park, Y.H., Park, J. et al. Metabolism and excretion study of DW116, a new fluoroquinolone, in rats. Arch. Pharm. Res. 20, 358–362 (1997). https://doi.org/10.1007/BF02976200
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02976200